Showing results (21-30 of 386) with videos related to
Sort By:
Pageof 39
Plos One|February 19, 2013
Activity of the heat shock protein 90 inhibitor ganetespib in melanomaXinqi Wu, Melina E Marmarelis, F Stephen HodiClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patientsPatrick A Ott, F Stephen Hodi, Caroline RobertJournal for Immunotherapy of Cancer|November 17, 2025
Endothelial cells as targets of immune checkpoint blockadeAlan J Korman, Matthew Taylor, F Stephen HodiEclinicalmedicine|December 25, 2024
Gaps in the management of adrenal insufficiency in melanoma survivors: a retrospective cohort studyWei Lin, Wei Wang, F Stephen Hodi, et al.Nature Reviews. Cancer|April 6, 2012
From genes to drugs: targeted strategies for melanomaKeith T Flaherty, F Stephen Hodi, David E FisherCurrent Opinion in Oncology|April 20, 2010
Mutation-driven drug development in melanomaKeith T Flaherty, F Stephen Hodi, Boris C BastianFrontiers in Oncology|October 7, 2015
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical DataPatrick A Ott, F Stephen Hodi, Elizabeth I BuchbinderNature Reviews. Cancer|October 13, 2020
Author Correction: From genes to drugs: targeted strategies for melanomaKeith T Flaherty, F Stephen Hodi, David E FisherClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2012
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1Daniel S Chen, Bryan A Irving, F Stephen HodiJCO Precision Oncology|September 11, 2020
Drug-Related Pneumonitis in the Era of Precision Cancer TherapyMizuki Nishino, Hiroto Hatabu, F Stephen Hodi, et al.Pageof 39